Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Surface Oncology, Inc. - Common Stock (NQ: SURF )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Surface Oncology, Inc. - Common Stock

< Previous 1 2 3 Next >
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 615 stocks hit new 52-week lows. Noteable 52-Week Lows: Sea (NYSE:SE) is the largest company in terms of market cap to set a new 52-week low this... 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Kiora Pharmaceuticals (NASDAQ:KPRX 
Via Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
Cathie Wood Goes Bargain Shopping -- 3 Troubled Stocks She Just Bought
The internet's favorite stock picker has been very busy. 
Via The Motley Fool
This Company Says It's One Step Closer to Transforming Cancer Treatment with its Latest Groundbreaking Immunotherapy
Photo by Martha Dominguez de Gouveia on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a... 
Via Benzinga
How To Lower Risk On Your Biotech Plays
You can hit some big home runs in the biotech sector, but you need to manage your risk when trading these stocks. If you handle your risk properly, you’ll be able to take more big swings. 
Via Talk Markets
Why AstraZeneca and Surface Oncology Rose Today
The pharmaceutical giant reports encouraging results from a late-stage ES-SCLC trial of blockbuster cancer treatment Imfinzi. 
Via The Motley Fool
35 Stocks Moving In Monday's Mid-Day Session
Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) jumped 145% to $6.86 after declining around 17% on Friday. Edesa Biotech, Inc. (NASDAQ: EDSA) jumped 30.6% to $7.68 after the company... 
Via Benzinga
Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026
Via FinancialNewsMedia
48 Biggest Movers From Friday
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) stock moved upwards by 53.98% to $3.48 during Friday's pre-market session. The company's market cap stands at $147.6... 
Via Benzinga
15 Stocks Moving in Friday's Pre-Market Session
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) rose 42% to $3.21 in pre-market trading. AbCellera Biologics Inc. (NASDAQ: ABCL) rose 18% to $23.35 in pre-market trading.... 
Via Benzinga
How Bad Are Surface Oncology's Earnings? | Return On Capital Employed
Surface Oncology (NASDAQ:SURF) brought in sales totaling $515.00 thousand during Q2 according to data provided by Benzinga Pro.However, earnings decreased 27.67%, resulting in a... 
Via Benzinga
iTeos Therapeutics Stock Surges On $2.1B Development Pact For EOS-448 With GSK
iTeos Therapeutics (NASDAQ: ITOS) and GlaxoSmithKline plc (NYSE: GSK) have agreed to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal... 
Via Benzinga
Surface Oncology's SRF388 Shows Promising Anticancer Activity in Pretreated Patients
Surface Oncology (NASDAQ: SURF) has announced new data from the ongoing Phase 1 studies of SRF388 and SRF617. SRF388 data will be presented at the American Society... 
Via Benzinga
Surface Oncology, Roche Team Up to Develop SRF388 Combo Therapy for Liver Cancer
Surface Oncology (NASDAQ: SURF) has entered into a clinical trial collaboration with Roche Holdings AG (OTC: RHHBY) to evaluate former's SRF388, anti... 
Via Benzinga
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Exposures Product Safety
This Is Why Surface Oncology Is a Great Stock to Buy Right Now
It's the right time to be decisive, if you can tolerate uncertainty. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2021
Upgrades Janney Montgomery Scott upgraded the previous rating for Centerspace (NYSE:CSR) from Neutral to Buy. In the first quarter, Centerspace showed an EPS of $0.95,... 
Via Benzinga
Could Surface Oncology Be a Millionaire-Maker Stock?
Investors looking for a shot at big gains from this clinical-stage biotech will need to be comfortable with making a speculative buy. 
Via The Motley Fool
Cathie Wood Buys $26M Disney Shares And Sells $13M In Netflix: What You Need To Know
Cathie Wood-led Ark Investment Management on Friday bought 150,556 shares, worth about $26.15 million, in Walt Disney Co (NYSE: DIS), marking its debut in the media and... 
Via Benzinga
5 Value Stocks In The Healthcare Sector
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples... 
Via Benzinga
Cathie Wood Cuts Apple Stake By 30% And Buys Coinbase, DraftKings
Cathie Wood-led Ark Investment Management shed more shares of Apple Inc (NASDAQ: 
Via Benzinga
Cathie Wood Loads Up More On Peloton, Skillz, Teladoc On The Dip
Cathie Wood-led Ark Investment Management snapped up over 3 million shares, worth about $48.53 million, in Skillz Inc (NYSE: SKLZ) on Wednesday. SKLZ shares closed 9% lower... 
Via Benzinga
Cathie Wood Slashes Apple Stake To Half — Also Trims Google, Fastly: What You Need To Know
Cathie Wood-led Ark Investment Management nearly halved the Apple Inc (NASDAQ: AAPL) stake in the ARK Fintech Innovation ETF (NYSE: ARKF) on Thursday. ARKF shed 298,505 Apple... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.